Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value ...

Would establish an innovative pharma services company with capabilities spanning drug discovery and development, biologic manufacturing and drug delivery technologiesWould meaningfully diversify, scale and extend Halozyme's revenue and adjusted EBITDA well into the next decade and beyondAll-cash transaction would be funded by cash on hand and new debt with expected pro forma net leverage less than 2x two years post close SAN DIEGO, Nov. 18, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("H ...

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry TeamSAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of Evotec SE (NASDAQ: EVO) ("Evotec") to acquire Evotec for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. T ...

Join Compounding Healthcare where we employ data analytics in combination with technical analysis and clinical data breakdown in order to manage a position in numerous potential multi-bagger investments that can grow into a comprehensive healthcare portfolio.It has been over two years since my previous Halozyme (NASDAQ: HALO ) article , where I discussed Halozyme's acquisition of Antares Pharma for roughly $960M, which was expected to improve their growth trajectory thanks to the addition of Antares Pharma' ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Core Viewpoint - Halozyme Therapeutics, Inc. reported strong third-quarter 2024 results, with adjusted earnings significantly exceeding expectations and a notable increase in total revenues, prompting an upward revision of its financial guidance for the year [1][2]. Financial Performance - Adjusted earnings for Q3 2024 were $1.27 per share, surpassing the Zacks Consensus Estimate of 99 cents and up from 75 cents per share in the same quarter last year [1]. - Total revenues for the third quarter reached $290 million, marking a 34% year-over-year increase and exceeding the Zacks Consensus Estimate of $248 million [1][2]. Revenue Breakdown - Royalty revenues amounted to $155.1 million, a 36% increase from the previous year, driven by strong demand for Phesgo and subcutaneous Darzalex, and exceeded the model estimate of $134.5 million [4]. - Product sales were $86.7 million, nearly matching the previous year's figure and beating the model estimate of $76.7 million [6]. - Revenues from collaborative agreements rose significantly to $48.4 million from $15 million in the prior year [7]. Adjusted EBITDA and Cash Position - Adjusted EBITDA for Q3 was $184 million, reflecting a 60% increase from the prior year [7]. - As of September 30, 2024, the company had cash, cash equivalents, and marketable securities totaling $666.3 million, up from $529 million as of June 30, 2024 [7]. 2024 Financial Guidance - Halozyme raised its 2024 revenue guidance to a range of $970 million to $1.02 billion, indicating year-over-year growth of 13% to 22% [8]. - Royalty revenues are now expected to be between $550 million and $565 million, an increase from the previous estimate of $520 million to $555 million [8]. - Collaboration revenues are projected to contribute $130 million to $150 million, while product sales are anticipated to be in the range of $290 million to $305 million for 2024 [9]. - Adjusted EBITDA is expected to be between $595 million and $625 million, representing a growth of 40% to 47% year-over-year [9]. - The company forecasts adjusted earnings per share in the range of $4.00 to $4.20, indicating an improvement of 44% to 52% year-over-year [10].

Financial Data and Key Metrics Changes - Total revenues increased by 34% to reach an all-time high of $290 million in Q3 2024, driven largely by a 36% increase in royalty revenue to $155 million [7][63] - Adjusted EBITDA grew by 60% to $183.6 million, while non-GAAP earnings per share increased by 69% to $1.27 [62][66] - The company raised its full-year revenue guidance to $970 million to $1.20 billion, representing a year-over-year increase of 17% to 23% [68][70] Business Line Data and Key Metrics Changes - Royalty revenues from subcutaneous DARZALEX, Phesgo, and VYVGART Hytrulo were the main drivers of growth, with DARZALEX sales increasing almost 23% and Phesgo sales up 58% [22][26][64] - Collaboration revenues rose significantly to $48.4 million, compared to $15 million in the prior year, due to the expansion of the Argenx collaboration [64] Market Data and Key Metrics Changes - The U.S. approval of Roche's TECENTRIQ and OCREVUS subcutaneous formulations is expected to expand market opportunities significantly, with Roche projecting a $2 billion market expansion for OCREVUS [10][31][76] - Analysts predict TECENTRIQ will achieve $5 billion in sales by 2028, with a significant portion coming from the conversion of intravenous to subcutaneous administration [30] Company Strategy and Development Direction - The company is focused on expanding its ENHANZE drug delivery technology through new partnerships and licensing agreements, with recent expansions including argenx's nomination of four additional targets [9][17] - The strategy emphasizes market growth rather than immediate conversion from IV to subcutaneous, particularly for OCREVUS, which aims to attract new prescribers [75][81] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued double-digit growth driven by multiple product launches and regulatory approvals, setting the stage for a strong start to 2025 [72][54] - The company highlighted the importance of its intellectual property portfolio in supporting revenue streams and enabling new partnerships [55][60] Other Important Information - The company maintains a strong balance sheet with cash and marketable securities totaling $666.3 million as of September 30, 2024 [67] - The MDASE patent portfolio has been expanded, with nearly 100 patents granted or pending, providing additional opportunities for licensing [59][116] Q&A Session Summary Question: Current view on sub-Q conversion for OCREVUS and TECENTRIQ - Management clarified that OCREVUS aims for market growth rather than immediate conversion, projecting a $2 billion market expansion, while TECENTRIQ will focus on converting existing patients to subcutaneous [75][76][81] Question: Contextualizing the $2 billion market expansion for OCREVUS - Management indicated that the $2 billion is additional to the existing IV sales, suggesting a total market growth to approximately $11 billion [81] Question: Status of new collaboration deals before year-end - Management confirmed ongoing efforts to secure new deals, with guidance for collaboration revenue set at $130 million to $150 million [87][88] Question: Differentiation of MDASE from ENHANZE - Management explained that MDASE involves different structures and is not expected to infringe on existing ENHANZE partnerships, as they cater to different needs [111][114] Question: Examples of partners unable to work with ENHANZE - Management noted that partners might choose modified hyaluronidase if they cannot work with ENHANZE due to exclusive licensing agreements [120] Question: Drivers behind the collaboration revenue guidance - Management acknowledged a slight reduction in the top range of collaboration revenue guidance, attributing it to current visibility on potential deals [119]

Halozyme Therapeutics, Inc. Third Quarter 2024 Financial & Operating Results 1 NASDAQ: HALO October 31, 2024 Forward Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future growth, financial performance (including the Company's 2024 guidance and longer term financial outlook through 2028) and expectations for profitability, revenue (including e ...

Halozyme Therapeutics (HALO) reported $290.08 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 34.3%. EPS of $1.27 for the same period compares to $0.75 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $248.01 million, representing a surprise of +16.97%. The company delivered an EPS surprise of +28.28%, with the consensus EPS estimate being $0.99.While investors closely watch year-over-year changes in headline numbers -- revenue an ...

Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.75 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 28.28%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.78 per share when it actually produced earnings of $0.91, delivering a surprise of 16.67%.Over the last fou ...